Severe Ehrlichia chaffeensis Infection in a Patient Receiving Etanercept, a Tumor Necrosis Factor Inhibitor

Abstract

Abstract

We report a patient receiving etanercept, a tumor necrosis factor inhibitor, who developed a severe Ehrlichia chaffeensis infection. Etanercept is associated with an increased risk of various infections. This is one of the first reported cases of ehrlichiosis in such a patient. This case may serve to alert clinicians of the possible susceptibility to severe E. chaffeensis infections for patients receiving etanercept.